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A molecularly cloned attenuated strain of Venezuelan equine encephalitis virus (VEE) has been genetically
configured as a replication-competent vaccine vector for the expression of heterologous viral proteins (N. L.
Davis, K. W. Brown, and R. E. Johnston, J. Virol. 70:3781–3787, 1996). The matrix/capsid (MA/CA) coding
domain of human immunodeficiency virus type 1 (HIV-1) was cloned into the VEE vector to determine the
ability of a VEE vector to stimulate an anti-HIV immune response in mice. The VEE-MA/CA vector replicated
rapidly in the cytoplasm of baby hamster kidney (BHK) cells and expressed large quantities of antigenically
identifiable MA/CA protein. When injected subcutaneously into BALB/c mice, the vector invaded and repli-
cated in the draining lymphoid tissues, expressing HIV-1 MA/CA at a site of potent immune activity. Anti-
MA/CA immunoglobulin G (IgG) and IgA antibodies were present in serum of all immunized mice, and titers
increased after a second booster inoculation. IgA antibodies specific for MA/CA were detected in vaginal
washes of mice that received two subcutaneous immunizations. Cytotoxic T-lymphocyte responses specific for
MA/CA were detected following immunization with the MA/CA-expressing VEE vector. These findings dem-
onstrate the ability of a VEE-based vaccine vector system to stimulate a comprehensive humoral and cellular
immune response. The multifaceted nature of this response makes VEE an attractive vaccine for immunization
against virus infections such as HIV-1, for which the correlates of protective immunity remain unclear, but may
include multiple components of the immune system.
The development of a vaccine against human immunodefi-
ciency virus type 1 (HIV-1) has proven to be more difficult than
first anticipated (42). Recent studies have demonstrated that
immunity to infection is possible; however, the mechanisms of
this protection remain poorly defined (17). These studies sug-
gest that protection may be mediated either by an individual
component of the immune system or through a combination of
humoral immunity in the form of neutralizing antibodies (15,
23, 37), mucosal immunity (40, 50), and cellular immunity (28,
47). Until the correlates of protection are better understood,
development of vaccines that simultaneously stimulate multi-
ple components of the immune system would be desirable (42).
One approach to the development of HIV vaccines is the use
of live-virus or bacterial vectors for the in vivo expression of
lentivirus gene products (1, 11, 19, 20, 26, 38, 40, 41, 43). For
example, strategies priming with recombinant vaccinia virus or
canarypox virus vectors expressing HIV immunogens followed
by booster inoculations with glycoprotein or peptides have
been tested in primate HIV or simian immunodeficiency virus
(SIV) challenge models. Many of these approaches afforded
protection against homologous viral challenge, but protection
against heterologous viral challenge was more variable (3, 11,
12, 20, 49).
The suitability of alphaviruses as viral expression vectors has
been described previously (21, 46). These positive-stranded
RNA viruses infect a broad range of host cells and initiate a
rapid replication cycle within the cytoplasm (51). Expression of
the structural proteins is controlled by a subgenomic mRNA
promoter which transcribes message at levels 10-fold that of
the genome. Alphavirus expression vectors have utilized this
strong viral subgenomic mRNA promoter, either by replacing
the viral structural protein genes with a foreign gene resulting
in a defective recombinant (2, 32, 38, 52–54) or by adding a
duplicate copy of the promoter to express the foreign gene, as
was done here, resulting in a fully replicative recombinant virus
(14, 33, 34). We have previously engineered an attenuated
vaccine candidate strain of the alphavirus Venezuelan equine
encephalitis virus (VEE) for the expression of heterologous
viral proteins (8).
There are a number of features of VEE which suggest it may
be unusually well suited as a viral vaccine vector, especially
against HIV-1. First, parenteral immunization of rodents, pri-
mates, and humans with live attenuated VEE vaccines results
in protection against lethal VEE challenge, not only via a
parenteral route, but also after intranasal or aerosol challenge
(6, 7, 22, 27, 44). This suggests that an HIV vaccine delivery
strategy using VEE-based vectors could induce protection
against invasion across a mucosal surface. This hypothesis was
tested by immunizing mice by subcutaneous (s.c.) inoculation
with a VEE vector expressing influenza virus hemagglutinin
(HA) (8). The VEE-HA vector afforded complete protection
against disease after a subsequent intranasal challenge with
influenza virus. Influenza virus replication in the nasal mucosa
was reduced, demonstrating that this protection extended to
the mucosal surface itself. Second, unlike vaccinia virus, polio-
virus, adenovirus, herpesvirus, and influenza virus-based vac-
cine vectors, most of the human population has never been
exposed to VEE. Therefore, immunization to HIV with a
VEE-based vector would not be restricted by preexisting im-
munity to the vector itself. Finally, unlike other alphaviruses,
VEE is lymphotrophic (24). After s.c. inoculation, replication
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is first detected in the lymph nodes draining that site. This
attribute confers the ability to specifically target the expression
of a heterologous protein to lymphoid tissues, where one might
expect the initiation of a vigorous immune response (29, 31,
32).
To test the ability of a VEE-based vector to induce a com-
plete immune response against an HIV immunogen, the ma-
trix/capsid (MA/CA) coding region of the HIV-1 gag gene was
cloned under the control of an additional VEE mRNA sub-
genomic promoter. The matrix and capsid proteins were cho-
sen because they are major structural components of the
HIV-1 virion, representing the N-terminal portion of the Gag
precursor protein, and contain known murine cytotoxic T-lym-
phocyte (CTL) epitopes. Immunization with MA/CA alone
might not be expected to provide protective immunity in hu-
mans, but MA/CA as a constituent of a vaccine together with
gp160 and other HIV immunogens should elicit a broader
immune response which may be sufficient to provide protec-
tion. Humoral and cellular immune responses directed against
the matrix and capsid proteins are readily detectable during
HIV infection in humans (17).
In mice inoculated parenterally, the VEE-MA/CA vector
targeted lymphoid tissue, resulting in the generation of hu-
moral and cellular responses specific for HIV MA/CA. In
addition, anti-MA/CA immunoglobulin A (IgA) antibodies
were detected in mucosal secretions from vaginal washes.
These findings suggest the suitability of the VEE vector to
elicit humoral, mucosal, and cellular immunity.
MATERIALS AND METHODS
Clones and viruses. The attenuated VEE vector has been described previously
(8). Briefly, the full-length cDNA of the virulent Trinidad donkey strain of VEE
was altered to contain two independently attenuating mutations (E2 Lys 209 and
E1 Thr 272) (9, 13). This attenuated mutant (pV3014) was engineered further to
express heterologous genes with the introduction of a duplicate copy of the 26S
subgenomic mRNA promoter inserted immediately downstream of the E1 gene.
The cloned cDNA of the complete MA/CA gene of HIV strain HXB2 (45)
(nucleotides [nt] 336 to 1424) was amplified by PCR (Perkin-Elmer Cetus) for 25
cycles with Taq DNA polymerase (Gibco, BRL) with primer addition of SalI
restriction sites to the 59 and 39 ends to facilitate introduction into a shuttle
vector multiple cloning site. The myristylation signal encoded at the 59 end of the
matrix coding domain was removed with the alteration of Gly 2 to Ala (nt 310
changed from G to C) encoded by the amplification primers. The upstream
primer sequence was 59 TCCCAACACTGTCGACAGTCTAGTCCGCCAAGA
TGGCTGCGAGAGCGTCAGTATTA 39. The downstream primer sequence
was 59 CTTGGCTCATGTCGACTTACAAAACTCTTGCCTTATG 39, where
italics indicate the SalI sites and the underlining indicates 16 nt of the 59
untranslated region of the VEE subgenomic mRNA added upstream of the
MA/CA AUG to retain the context of the subgenomic promoter. The boldface
letters indicate the initiation and termination codons in the upstream and down-
stream primers, respectively.
The MA/CA coding domain was transferred from the shuttle vector into the
full-length pV3014 background with ClaI. The insert and the additional pro-
moter were sequenced (TaqDNA cycle sequencing procedure; U.S. Biochemical
Corp.) to ensure no alterations were introduced during generation of the clone.
Infectious transcripts were generated by in vitro transcription of cDNA clones
linearized with NotI with T7 RNA polymerase (Gibco, BRL). Electroporation of
baby hamster kidney (BHK) cells produced progeny virus stocks after 24 h of
incubation at 378C (10). The specific infectivity of the vector RNA transcripts,
plaque morphology, and growth kinetics of the vector virions closely resembled
those of the parental attenuated V3014 virus.
Immunization of mice. Six-week-old female BALB/c mice were obtained from
Charles River Laboratories (Wilmington, Mass.). Mice were acclimatized for 1
week in the BL-3 laboratory with sterile bedding and cages prior to any proce-
dure.
Mice were inoculated s.c. in both rear footpads with 104 PFU of VEE-MA/CA
vector in diluent (phosphate-buffered saline [PBS] with 1% donor calf serum)
under light Metofane anesthesia (Pitman-Moore). Control mice were mock
immunized with diluent alone or VEE vector without insert. Booster immuni-
zations were performed 3 weeks postpriming with an increased virus concentra-
tion of 105 PFU per rear footpad.
Polyacrylamide gel analysis of [35S]methionine-labeled viral proteins. BHK
cell monolayers (107 cells) were infected with VEE vector virus at 378C at a
multiplicity of infection of 10 and were incubated in methionine-free media
between 6 and 10 h postinfection. Ten hours postinfection, cells were washed and
placed in medium containing [35S]methionine (20 mCi/ml) for 2 h. Twelve hours
postinfection, cytoplasmic extracts were prepared by lysis in 1 ml of lysis buffer
with protease inhibitors (0.05 M Tris-HCl [pH 7.5], 0.1 M NaCl, 0.001 M EDTA,
0.2% Nonidet P-40, 1 mM leupeptin, 1 mM pepstatin, and 0.2 mM phenylmeth-
ylsulfonyl fluoride). Nuclei were removed by centrifugation at 11,000 3 g for 1
min. Labeled cytoplasmic proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (10% polyacrylamide; stock
30% [wt/vol] acrylamide, 0.8% [wt/vol] bisacrylamide; Protogel; National Diag-
nostics) under reducing conditions (50 mM 2-mercaptoethanol) (30). Protein
bands on gels were visualized by Coomassie brilliant blue staining or fluorogra-
phy with Amplify (Amersham). Expression levels of MA/CA protein were de-
termined with an HIV p24 Core Profile enzyme-linked immunosorbent assay
(ELISA) kit (Dupont; NEK-060A).
Western blotting. Cell lysates were prepared as detailed in the previous sec-
tion. Western blotting was performed by standard methods (16). Briefly, proteins
were separated by SDS-PAGE through 15% acrylamide gels. After transfer onto
nitrocellulose, blots were blocked for 1 h in 2% bovine serum albumin in TBST
(10 mM Tris base [pH 8.0], 150 mM NaCl, 0.05% Tween 20). Blots were
incubated for 1 h with one of the following primary antibodies: mouse anti-HIV
p17 monoclonal antibody (Cellular Products, Buffalo, N.Y.), HIV-positive pa-
tient serum (BB6) (25), or anti-VEE hyperimmune mouse ascites fluid (HMAF)
diluted 1:2,000 in TBST. Secondary antibodies were anti-mouse or anti-human
IgG alkaline phosphatase-conjugated antibodies (Promega) diluted 1:4,000 in
TBST buffer. Blots were developed in 10 ml of bromochloroindolyl phosphate-
nitroblue tetrazolium substrate (BCIP/NBT) in 0.1 M Tris (pH 9.5)–0.1 M
NaCl–5 mM MgCl2 (Promega).
In situ hybridization. For in situ hybridization mice were inoculated s.c. in the
left rear footpad with 104 PFU of VEE-MA/CA vector in 10 ml of PBS–1% donor
calf serum or diluent only for controls. At 24 and 48 h postinoculation, two mice
per group were sacrificed, and draining popliteal lymph node, spleen, and thymus
tissues were harvested and fixed in 4% paraformaldehyde in PBS. Riboprobes for
the VEE structural genes (678 nt) and influenza virus (PR8 strain) HA gene (500
nt) (negative control) were generated as previously described (8, 13). To detect
HIV MA/CA-specific RNA, a pGEM-3 (Promega) clone containing the 627-nt
HindIII fragment of HXB2 (nt 631 to 1258) was linearized at the unique PvuII
site. In vitro Sp6 polymerase transcription reaction mixtures containing [a-35S]
UTP generated a 550-nt radiolabeled RNA probe complementary to MA/CA
message sense RNA. Probes were hybridized to paraffin-embedded sections
mounted on aminopropyl triethoxysilane-coated slides (ProbeOn Plus; Fisher
Scientific). Wash conditions were as previously described (13). Slides were
dipped in Kodak NTB-2 emulsion, dried, and exposed at 2708C for 144 h. After
development, slides were counterstained with Gill’s hematoxylin.
Antibody detection and titration. Serum samples were obtained from tail vein
bleeds 3 weeks after primary or secondary inoculation. ELISAs for the detection
of anti-VEE antibody used 250 ng of gradient-purified VEE virus per well as
antigen. The HIV MA/CA ELISA used 250 ng of bacterially expressed MA/CA
protein (the kind gift of H. Ke, Department of Biochemistry, University of North
Carolina, Chapel Hill) per well as an antigen. Secondary antibody was either
horseradish peroxidase-conjugated goat anti-mouse IgG or IgA (Sigma Immu-
nochemicals). Positive control antibodies were IgG and IgA anti-p24 mouse
monoclonal antibodies (Cellular Products) for MA/CA, and for the anti-VEE
ELISA, an anti-VEE HMAF. The ELISA titer was defined as the inverse of that
serum dilution giving an optical density at 450 nm greater than 0.2 above the
background (wells lacking serum). In all assays, normal sera and sera taken prior
to immunization were never positive at a 1:40 dilution, the lowest dilution tested.
Geometric mean titers were calculated for serum antibody titers from sets of four
mice.
Vaginal washes were assayed by the same ELISA protocols. Washes were
performed with 50 ml of PBS-D (Mg21 and Ca21 free) under light Metofane
anesthesia 7, 10, and 14 days after the booster immunization. Washes from four
individual mice were pooled and concentrated to a 50-ml final volume in Cen-
tricon columns (30-kDa exclusion limit; Amicon).
CTL culture and cytotoxicity assays. One week post-booster immunization,
splenocytes were harvested from VEE-MA/CA, vector alone, or PBS-inoculated
BALB/c (H-2d) mice. Spleen cells were stimulated in vitro with syngeneic feeder
cells infected with a recombinant vaccinia virus expressing the entire HIV-1 gag
gene (vv-gag). Splenocytes were cultured at 4.5 3 106/well in RPMI 1640 me-
dium (Mediatech, Washington, D.C.) containing 5% fetal calf serum (HyClone)
and 2 mM L-glutamine (GIBCO). Syngeneic feeder cells were prepared by
infection with either vv-gag or vaccinia virus-alone controls (vv-sc11) at a mul-
tiplicity of infection of 5 for 1 h. Excess virus was removed from the cells before
further incubation for 2 h at 378C. The cells were washed, UV treated for 30 min,
and irradiated with 20 Gy from a cesium source. Feeder cells were added to
splenocyte cultures at a 1:3 cell ratio, and 25 ng of human interleukin 7 per ml
was added (Endogen, Cambridge, Mass.).
Cultures were incubated for 7 days, after which dead cells and debris were
removed by centrifugation through a lympholyte M gradient (Cedarlane). Cul-
tures were restimulated on day 7 with feeder cells in RPMI complete media and
30% supernatant from concanavalin A-treated splenocytes. At day 14, cells were
purified through lympholyte M, and chromium release assays were performed.
Major histocompatibility complex (MHC)-matched P815 mastocytoma target
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cells were infected for 1 h with vv-gag. P815 cells infected with vaccinia virus
alone (vv-sc11) or noninfected cells were used as negative controls. Targets were
incubated for 18 h to allow gag expression, labeled with 51Cr for 1 h, washed, and
used in a standard 4-h chromium release assay (36).
RESULTS
Expression of HIV MA/CA protein in BHK cells. The
MA/CA coding domain of HIV strain HXB2 was cloned into a
VEE double-promoter expression vector (8) derived from a
highly attenuated, infectious VEE clone, pV3014 (13). The
myristylation site encoded in the MA/CA domain was mutated
during cloning to retain the protein in the cytoplasm to poten-
tiate processing and presentation by MHC class I proteins. To
determine if HIV MA/CA was expressed from the inserted
sequence, BHK cells were infected with the VEE-MA/CA vec-
tor or VEE vector alone and radiolabeled with [35S]methi-
onine, and cytoplasmic extracts were analyzed by PAGE. Both
the Coomassie brilliant blue-stained gel (Fig. 1A) and autora-
diograph (Fig. 1B) showed high-level expression of a protein
which migrated with the same apparent molecular weight as
MA/CA protein (lane 4 in Fig. 1A and B). The level of MA/CA
protein synthesis was comparable to that of the VEE viral
capsid, as well as the levels of some of the most predominant
cellular proteins. The retarded mobility of the VEE E1 glyco-
protein in lanes 3 and 4 (apparent molecular mass of 56 kDa)
compared to that in lane 2 in the autoradiograph (apparent
molecular mass of 51 kDa) (Fig. 1B) is due to the addition of
a glycosylation site at E1 position 272 in the attenuated mutant
vector background (V3014) which is absent in the wild-type
virus (V3000).
To identify the protein expressed by the VEE vector as HIV
MA/CA, cell lysate preparations were characterized by West-
ern immunoblotting with either anti-p17 monoclonal antibody
(Fig. 2A) or BB6 HIV-positive patient serum (Fig. 2B). A
protein of the correct molecular mass was detected in lysates
from cells infected with the VEE vector containing the MA/CA
coding domain in the sense orientation (lanes 1), but a reactive
protein was not detectable in cells infected with the antisense
orientation of the MA/CA domain insert (lanes 2), or after
infection with the VEE vector alone (lanes 3), or in mock-
infected cells (lanes 4). As a positive control, a Western blot
probed with anti-VEE polyclonal antibody stained reactive
VEE capsid and glycoproteins in all three VEE-infected but
not mock-infected cell lysates, as expected (Fig. 2C).
The quantity of MA/CA protein was estimated to be approx-
imately 40 mg/107 BHK cells by the HIV p24 Core Profile
ELISA standardized kit (Dupont). This was equivalent to 6 3
107 copies of MA/CA polypeptide/cell at 12 h postinfection.
The cytoplasmic levels of the heterologous protein were com-
parable to those of the VEE structural proteins.
HIV MA/CA expression in lymphoid tissue. Groups of four
BALB/c mice were inoculated s.c. in the left rear footpad with
104 PFU of VEE-MA/CA vector or VEE vector alone. In
VEE-MA/CA-inoculated mice sacrificed 24 h after inocula-
FIG. 1. PAGE of [35S]methionine-labeled cytoplasmic proteins from VEE-MA/CA vector-infected BHK cells. (A) Coomassie brilliant blue-stained gel. (B)
Autoradiograph of the same gel. Coelectrophoresed protein markers are indicated by molecular masses to the left. Proteins migrating at the position predicted for HIV
MA/CA and the VEE capsid are labeled. Mock-infected cells (lane 1), VEE (V3000) wild-type-infected cells (lane 2), VEE vector-alone-infected cells (lane 3), and
VEE-MA/CA-infected cells (lane 4) are shown.
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tion, a dense in situ hybridization signal was detected in the
draining left popliteal lymph node, indicating both MA/CA
and VEE mRNA expression (Fig. 3A and B, respectively). The
MA/CA- and VEE-specific mRNAs were colocalized to the
same foci, suggesting that the majority of infected cells ex-
pressed the MA/CA mRNA. No signal was detected in any
tissue with the HA-specific negative control probe (Fig. 3C).
Only VEE-specific signal was detected in mice infected with
the VEE vector without the insert or with the MA/CA probe
on tissues from mock-infected negative controls (results not
shown). Low levels of signal also were detected in the spleen,
but none were detected in the thymus of VEE MA/CA-inoc-
ulated mice. Mice sacrificed 48 h after inoculation showed a
similar pattern, with slightly decreased levels of signal in the
draining lymph node and very low levels in the spleen (results
not shown). This demonstrates that the VEE-MA/CA vector,
like its parental VEE strain, retained the ability to target rep-
lication, and hence expression of MA/CA, to lymphoid tissues.
Anti-MA/CA antibody responses in VEE-MA/CA vector-im-
munized mice. The ability to target expression of HIV MA/CA
to lymphoid tissue might be expected to result in a strong
immune response against the protein. To determine the ability
of the VEE-MA/CA vector to elicit a humoral immune re-
sponse, serum antibody levels were measured. Three weeks
post-primary inoculation and 3 weeks post-booster inoculation,
significant serum IgG and IgA anti-MA/CA levels were de-
tected (Fig. 4). Control animals inoculated with the VEE vec-
tor alone had no detectable anti-MA/CA titer at the lowest
dilution (1:40) after either the primary or boost inoculation.
All animals inoculated with the VEE-MA/CA vector mounted
significant anti-MA/CA serum IgG and IgA responses. These
responses were significantly increased after the booster inocu-
lation; individual mice all showed a significant increase in titer.
The geometric mean titers after the booster inoculation were
12,800 and 2,265 for serum anti-MA/CA IgG and IgA, respec-
tively. After the booster inoculation, increases in anti-VEE
IgG and IgA responses also were detected. This demonstrates
the ability to boost previously primed antibody responses to
FIG. 2. Western blots of BHK cell lysates infected with the VEE-MA/CA
vector. Blots were probed with a mouse anti-HIV p17 monoclonal antibody (A),
HIV-positive patient serum (BB6) (B), and anti-VEE HMAF polyclonal anti-
body (C). In each panel, BHK cells were infected with VEE-MA/CA vector with
the MA/CA coding domain in the sense orientation (lane 1), VEE-vector with
the MA/CA coding domain in the antisense orientation (lane 2), VEE vector
alone (lane 3), and mock-infected cell lysates (lane 4).
FIG. 3. Detection of HIV MA/CA mRNA expression in lymphoid tissue after
footpad inoculation of BALB/c mice. Popliteal lymph nodes were harvested from
mice 24 h postinoculation with the VEE-MA/CA vector. Serial sections of the
lymph nodes were subjected to in situ hybridization to detect specific mRNA ex-
pression. HIV MA/CA mRNA was detected with negative-sense 35S-UTP-la-
beled MA/CA-specific riboprobe (A). This signal was colocalized with VEE mRNA
detected in an adjacent section with a VEE-specific riboprobe (B). As a negative
control, an influenza virus HA-specific radiolabeled riboprobe hybridized to an ad-
jacent tissue section detected no message (C). Magnification,335. Bars, 200 mm.
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both MA/CA and VEE in the presence of a preexisting im-
mune response against the vector.
Anti-MA/CA and anti-VEE IgG levels were measured 3 and
6 months after the booster inoculation to determine the lon-
gevity of the humoral response. No decrease in titer was de-
tected, suggesting that a long-lived immunity had been induced
(results not shown).
Detection of anti-MA/CA-specific IgA antibodies in vaginal
washes. The most common route of natural infection for
HIV-1 is across a mucosal surface (50). A vaccine candidate
which could stimulate mucosal immunity against HIV might
prevent infection by this route. Mice were inoculated by the s.c.
route and given booster inoculations 3 weeks later. Vaginal
washes from each group of four mice (VEE-MA/CA or vector
alone) were pooled and concentrated. HIV MA/CA-specific
IgA antibodies were detected in vaginal washes from mice
inoculated with the VEE-MA/CA vector, but not in controls
(Fig. 5). This indicates the ability of the parenterally adminis-
tered VEE-MA/CA vector to generate detectable IgA levels
against an HIV antigen at the mucosal surface.
CTLs specific for HIV MA/CA. A likely requirement of a
successful HIV vaccine candidate would be the ability to elicit
a complete response, stimulating both humoral and cellular
arms of the immune system. To evaluate this in the VEE
system, we determined the ability of infected mice to generate
CTL responses specific for MA/CA. BALB/c mice were inoc-
ulated and given booster inoculations with VEE-MA/CA or
vector alone as described above. One week post-booster inoc-
ulation, splenocytes from each group were harvested, pooled,
and stimulated twice in vitro with syngeneic feeder cells in-
fected with either vaccinia virus alone (vv-sc11) or vaccinia
virus expressing HIV Gag (vv-gag). CTL activity was measured
with vaccinia virus-infected P815 target cells. A strong anti-
MA/CA CTL response was detected in splenocytes from mice
inoculated with the VEE-MA/CA vector. Cells from these
mice lysed vv-gag-infected targets, but failed to lyse vv-sc11-
infected or uninfected targets (Fig. 6A). Splenocytes from mice
inoculated with the VEE-MA/CA vector and stimulated in
vitro with feeder cells infected with vaccinia virus alone did not
kill any targets (Fig. 6B). Splenocytes from control mice inoc-
ulated with the VEE vector alone showed no activity after in
vitro stimulation (results not shown).
To examine the variability of the CTL response, individual
mice were also tested. Three of three mice which received the
VEE-MA/CA vector mounted a CTL response specific for
MA/CA (results not shown). These results indicate the ability
of the VEE vector to generate a consistent CTL response
directed against MA/CA-encoded epitopes.
DISCUSSION
The use of live-virus vaccine vectors for the expression of
HIV proteins is an active area of investigation. A number of
studies with vaccinia virus, picornaviruses, adenoviruses, her-
pesviruses, or influenza virus, as well as alphaviruses, as ex-
pression vectors all have shown the ability to elicit some degree
of immunity to HIV (46). Each virus vector has intrinsic ad-
vantages and disadvantages, such as feasibility for human use,
preexisting immunity to the vector itself, stability and size of
heterologous insert, as well as the strength, breadth, and lon-
gevity of the immune response elicited. It seems unlikely that
one vector will be optimal in all of the properties described
above. Therefore, a case can be made for the development and
testing of multiple vaccine vector candidates against HIV.
The experiments reported here demonstrate (i) that VEE
vaccine vectors are efficient expression systems for in vivo
delivery of HIV immunogens, (ii) that the response to the
expressed gene product can be enhanced by booster inocula-
tion, and (iii) that these vectors stimulate the cellular as well as
the humoral and mucosal arms of the immune system.
Expression levels of the foreign protein generated by the
VEE vector are comparable to levels of expression achieved in
Sindbis virus, vaccinia virus, and adenovirus vector systems
(52). We have found that heterologous genes approximately 1
kb in size are relatively stable and are retained during serial
tissue culture passage. Larger genes on the order of 2.5 kb,
such as those expressing the HIV and SIV envelope glycopro-
teins, can also be expressed by the vector, although these pro-
teins are not tolerated quite as well by the vector. This may be
FIG. 4. Geometric mean serum antibody titers detected against HIVMA/CA
or VEE. BALB/c mice received a primary s.c. inoculation and were given a
booster inoculation 3 weeks later with the VEE-MA/CA vector. There were four
mice per sample group. Antibody titers were measured by ELISA as described in
Materials and Methods. Solid bars, anti-MA/CA serum IgA or IgG levels 3 weeks
after primary inoculation with the VEE-MA/CA vector; hatched bars, anti-
MA/CA levels 3 weeks after booster inoculation; shaded bars, anti-VEE titers
after primary inoculation; open bars, anti-VEE titers after the booster inocula-
tion. Error bars indicate 1 standard deviation.
FIG. 5. Detection of anti-MA/CA IgA-specific antibodies in vaginal washes
of mice immunized and given booster inoculations with the MA/CA vector or
vector alone. Vaginal wash samples were pooled and analyzed by ELISA to
detect MA/CA-specific IgA antibodies at the mucosal surface. Mice were immu-
nized (primary and booster) with the MA/CA vector (F) or with VEE vector
alone (E). Preimmunization and pre-booster antibody levels (not shown) were
the same as those in the vector-alone group. O.D., optical density.
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due to size of the insert or the nature of the protein being
expressed (5).
We previously have demonstrated the efficacy of a VEE-
based vaccine vector expressing influenza virus HA in a mu-
cosal challenge model (8). Mice immunized parenterally with
the VEE-HA vector not only survived an otherwise lethal
intranasal inoculation of virulent influenza virus, but were to-
tally protected from disease. Protection was evident at the
mucosal surface, as shown by reduced replication of influenza
virus in the nasal respiratory epithelium. This study suggested
that VEE could be a useful vaccine vector for pathogens such
as HIV which enter across a mucosal surface.
To test the potential of VEE-based vaccine vectors to stim-
ulate an immune response to a lentivirus immunogen, we ex-
pressed the matrix/capsid region of the HIV gag gene. Both
humoral and cellular responses are mounted against the Gag
protein in a natural infection, and core antigens may be an
important component of a vaccine (18, 35). The VEE vector
expressed high levels of HIV MA/CA protein in cell culture. In
vivo, it produced no signs of infection upon s.c. inoculation
because of the presence of two independently attenuating mu-
tations in the glycoprotein genes (13).
Previous studies have shown that specifically targeting the
iliac lymph node with an SIV envelope and core subunit vac-
cine provides protection against SIV challenge in macaques
(31, 32). Here we show that the VEE-MA/CA vector was
specifically targeted to the draining lymph node, where expres-
sion was readily detected by in situ hybridization. This suggests
that the lymphoid targeting demonstrated by VEE may be a
highly desirable characteristic for a vaccine vector, in that
foreign protein expression is concentrated at a site of high
immune activity. The molecular mechanisms underlying this
lymphoid targeting are under active investigation.
The VEE vector efficiently elicited a humoral antibody re-
sponse to HIV MA/CA in all mice tested. Both serum IgG and
IgA antibodies were detected, indicating class switching had
occurred. The humoral immune response elicited in mice given
booster inoculations with the VEE-MA/CA vector was long
lived, because serum IgG levels were undiminished at 6 months
post-booster inoculation. The addition of a second inoculation
significantly increased antibody titers in all mice. This was
somewhat surprising, considering the preexisting levels of anti-
VEE neutralizing antibodies elicited during the primary vector
immunization (5). This may reflect the ability of the vaccine
vector, when inoculated s.c., to efficiently traffic to the local
lymph nodes by a route not exposed to high levels of circulating
neutralizing antibody. Alternatively, achieving a secondary re-
sponse to MA/CA in the presence of anti-VEE neutralizing
antibodies may require much lower expression than that re-
quired to prime the response initially. Experiments are in
progress to test the ability of these vectors to prime a response
to a heterologous immunogen in a VEE immune host. These
considerations suggest that booster inoculation strategies will
be important in the design of VEE vaccines and VEE vaccine
vectors.
In addition to the strong serum antibody response detected
in the sera of mice inoculated with the vector, we detected
anti-MA/CA IgA antibodies at the mucosal surface in vaginal
washes. The mucosal immune system may play an important
role in protective vaccination against HIV (50), and the ability
of a vaccine candidate to generate antibodies both in the serum
and at mucosal surfaces is a desirable characteristic. However,
the mechanism by which these antibodies reached the vaginal
mucosa is not understood. Two possibilities are transudation of
IgA from the serum across the mucosal epithelium or secretion
of IgA at the mucosal surface itself (39, 50). An s.c. inoculation
of the parental attenuated virus, upon which the vector is
based, provides protection against virulent VEE challenge at a
mucosal surface, and the immunizing virus replicates in lym-
phoid tissue, including Peyer’s patches, in the gut-associated
lymphoid tissue (6). Whether VEE vectors also target lym-
phoid tissues in the gut and genital mucosa remains to be
determined.
The cellular immune system is thought to play an integral
role in the initial response to HIV infection. Cellular immune
responses are believed to reduce viral load and may be respon-
sible for viral clearance or immune protection in a small num-
ber of cases (17). We have shown the ability of the VEE
vaccine vector to raise a cellular immune response specific for
HIV MA/CA protein. Every animal inoculated with the vector
raised a cellular response, with significant lysis at effector/
target ratios as low as 6:1. The longevity of the cellular re-
sponse elicited by the VEE vector is currently under investi-
gation. The cellular immune response to MA/CA is probably
FIG. 6. CTL response specific for HIV MA/CA elicited in mice primed and given booster inoculations with the VEE-MA/CA vector. Splenocytes harvested from
BALB/c mice 1 week post-booster inoculation with the MA/CA vector were stimulated twice in vitro with vv-gag (A)- or vv-sc11 (B)-infected syngeneic feeder cells.
Cr51-release CTL assays were performed to detect HIV MA/CA CTLs. P815 target cells were infected with vv-gag (■) or vv-sc11 (F) or were mock infected (E). The
percent specific lysis for each effector/target (E:T) ratio was calculated as described in Materials and Methods.
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the more relevant response to this antigen, since matrix and
capsid are present either inside the infected cell or inside the
viral particle and are thus not exposed to neutralizing antibod-
ies.
Safety issues are a major concern in the rational design of
any vaccine. A VEE-based vaccine system has good potential
for human use, as judged by a number of studies evaluating the
use of live attenuated VEE vaccines. TC-83 is the only alpha-
virus vaccine tested extensively in humans to date (4). More
recently, live attenuated strains of VEE with improved efficacy
and safety in rodents (9), horses and primates (44), have been
developed. These candidates (including the strain used for the
VEE vector described here) provide improved protection com-
pared to the existing TC-83 vaccine strain. They have the
added benefit of not producing a serum viremia in rodents
sufficient to support spread by mosquito vectors (13) and are
unlikely to produce such a viremia in humans (48).
In conclusion, we have shown that a VEE-based vaccine
vector expresses high levels of HIV MA/CA. The vector tar-
geted expression of MA/CA protein to the lymph nodes, elic-
iting a strong humoral and cellular immune response in the
periphery. The vector also generated MA/CA-specific IgA an-
tibodies in the genital mucosa. This suggests that VEE-based
vaccine vectors can stimulate multiple arms of the immune
system to elicit a comprehensive immune response against
HIV immunogens. Future studies will include expression of
HIV glycoproteins and SIV immunogens, to allow the efficacy
of VEE vectors to be tested in a primate challenge model.
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ADDENDUM IN PROOF
After this article was accepted for publication, the humoral
and cellular responses elicited against HIV MA/CA were de-
termined at 11 months post-booster inoculation. HIVMA/CA-
specific serum IgG and IgA levels were found to be undimin-
ished, and bulk CTL assays detected MA/CA-specific lysis in
splenocytes from 4 of 4 mice primed and boosted with the
VEE-MA/CA vector.
REFERENCES
1. Altmeyer, R., N. Escriou, M. Girard, A. Palmenberg, and S. van der Werf.
1994. Attenuated Mengo virus as a vector for immunogenic human immu-
nodeficiency virus type 1 glycoprotein 120. Proc. Natl. Acad. Sci. USA 91:
9775–9779.
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